Passage Bio (NASDAQ:PASG – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a report released on Thursday,Benzinga reports. They currently have a $7.
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Passage Bio (PASG – Research Report) yesterday and set a price target ...
Passage Bio, Inc. ( (PASG)) has released its Q3 earnings. Here is a breakdown of the information Passage Bio, Inc. presented to its investors. Passage Bio, Inc. is a clinical-stage genetic medicines ...
"This quarter, we've made important strides in advancing our PBFT02 gene therapy program,” said Will Chou, M.D., president and chief executive officer of Passage Bio. "Execution of our ongoing ...
“This quarter, we've made important strides in advancing our PBFT02 gene therapy program,” said Will Chou, M.D., president and chief executive officer of Passage Bio.“Execution of our ...
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, ...
“This quarter, we’ve made important strides in advancing our PBFT02 gene therapy program,” said Will Chou, M.D., president and chief executive officer of Passage ...
Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and ...
PHILADELPHIA - Passage Bio, Inc. (NASDAQ:PASG), a genetic medicines company, presented promising preclinical and interim clinical data for its gene therapy product, PBFT02, at the... PHILADELPHIA ...
PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...
(MENAFN- GlobeNewsWire - Nasdaq) PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of ...
MyChesCo on MSN8d
Passage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference!PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that Will Chou, M.D., the president and chief executive officer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback